US 11,717,568 B2
MVA vaccine for delivery of a UL128 complex and preventing CMV infection
Don J. Diamond, Glendora, CA (US); and Felix Wussow, Duarte, CA (US)
Assigned to CITY OF HOPE, Duarte, CA (US)
Filed by CITY OF HOPE, Duarte, CA (US)
Filed on Nov. 20, 2020, as Appl. No. 17/100,573.
Application 17/100,573 is a continuation of application No. 16/538,668, filed on Aug. 12, 2019, granted, now 10,842,864.
Application 16/538,668 is a continuation of application No. 15/919,110, filed on Mar. 12, 2018, granted, now 10,376,575, issued on Aug. 13, 2019.
Application 15/919,110 is a continuation of application No. 14/606,973, filed on Jan. 27, 2015, granted, now 9,931,395, issued on Apr. 3, 2018.
Application 14/606,973 is a continuation of application No. PCT/US2013/032554, filed on Mar. 15, 2013.
Claims priority of provisional application 61/676,846, filed on Jul. 27, 2012.
Prior Publication US 2021/0177962 A1, Jun. 17, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/245 (2006.01); C07K 14/005 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/245 (2013.01) [A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/70 (2013.01); C12N 2710/16122 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/24143 (2013.01); C12N 2799/023 (2013.01); C12N 2800/204 (2013.01)] 13 Claims
 
1. A method for treating a CMV infection in a subject comprising: administering to the subject a therapeutically effective amount of a CMV vaccine, and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof,
wherein the CMV vaccine comprises a modified vaccinia Ankara (MVA) viral vector expressing a set of five CMV proteins or antigenic fragments thereof that form a UL128 complex,
thereby treating the CMV infection in the subject.